Titan Pharmaceuticals, Inc. (TTNP): Price and Financial Metrics

Titan Pharmaceuticals, Inc. (TTNP): $7.08

0.10 (+1.43%)

POWR Rating

Component Grades








Add TTNP to Watchlist
Sign Up

Industry: Biotech




#256 of 397

in industry

TTNP Price/Volume Stats

Current price $7.08 52-week high $16.59
Prev. close $6.98 52-week low $5.00
Day low $6.55 Volume 13,200
Day high $7.08 Avg. volume 9,092
50-day MA $6.86 Dividend yield N/A
200-day MA $7.61 Market Cap 6.47M

TTNP Stock Price Chart Interactive Chart >

Titan Pharmaceuticals, Inc. (TTNP) Company Bio

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company was founded in 1992 and is based in South San Francisco, California.

TTNP Latest News Stream

Event/Time News Detail
Loading, please wait...

TTNP Latest Social Stream

Loading social stream, please wait...

View Full TTNP Social Stream

Latest TTNP News From Around the Web

Below are the latest news stories about TITAN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TTNP as an investment opportunity.

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately.

Yahoo | October 16, 2023

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i)

Yahoo | September 18, 2023

Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide

Investigating the valuation of Titan Pharmaceuticals Inc (TTNP) and its potential for future returns

Yahoo | August 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday!

William White on InvestorPlace | July 28, 2023

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net salesSAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfoli

Yahoo | July 27, 2023

Read More 'TTNP' Stories Here

TTNP Price Returns

1-mo 6.05%
3-mo 12.56%
6-mo 26.88%
1-year -52.74%
3-year -85.55%
5-year -99.17%
YTD -14.18%
2023 -47.32%
2022 -23.23%
2021 -69.00%
2020 -43.50%
2019 -85.30%

Continue Researching TTNP

Here are a few links from around the web to help you further your research on Titan Pharmaceuticals Inc's stock as an investment opportunity:

Titan Pharmaceuticals Inc (TTNP) Stock Price | Nasdaq
Titan Pharmaceuticals Inc (TTNP) Stock Quote, History and News - Yahoo Finance
Titan Pharmaceuticals Inc (TTNP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!